Status:
RECRUITING
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Intestinal Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to fir...
Detailed Description
Neuromuscular blocking agents are essential during surgical procedures to paralyze the body to avoid unnecessary movement during surgery. There are various medications, such as Sugammadex that are lat...
Eligibility Criteria
Inclusion
- Age 18 or older
- Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
Exclusion
- Allergy to Rocuronium, Vecuronium, or Sugammadex
- Bowel resection surgery requiring an ostomy
- No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
- No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
- Creatinine Clearance (CrCl) of less than 30
- Pregnancy
- Incapable of providing consent or understanding the research project
Key Trial Info
Start Date :
April 17 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT06112353
Start Date
April 17 2024
End Date
July 31 2026
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Irvine Medical Center
Orange, California, United States, 92868